WO1997004748A3 - Enhanced artificial viral envelopes for cellular delivery of therapeutic substances - Google Patents
Enhanced artificial viral envelopes for cellular delivery of therapeutic substances Download PDFInfo
- Publication number
- WO1997004748A3 WO1997004748A3 PCT/US1996/012750 US9612750W WO9704748A3 WO 1997004748 A3 WO1997004748 A3 WO 1997004748A3 US 9612750 W US9612750 W US 9612750W WO 9704748 A3 WO9704748 A3 WO 9704748A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vesicles
- therapeutic substances
- artificial viral
- envelopes
- nucleic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU66914/96A AU6691496A (en) | 1995-08-01 | 1996-08-01 | Enhanced artificial viral envelopes for cellular delivery of therapeutic substances |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US173895P | 1995-08-01 | 1995-08-01 | |
US60/001,738 | 1995-08-01 | ||
US258095P | 1995-08-21 | 1995-08-21 | |
US60/002,580 | 1995-08-21 | ||
US69061396A | 1996-07-31 | 1996-07-31 | |
US60/690,613 | 1996-07-31 |
Publications (4)
Publication Number | Publication Date |
---|---|
WO1997004748A2 WO1997004748A2 (en) | 1997-02-13 |
WO1997004748A3 true WO1997004748A3 (en) | 1997-05-29 |
WO1997004748B1 WO1997004748B1 (en) | 1997-07-17 |
WO1997004748A9 WO1997004748A9 (en) | 1997-10-09 |
Family
ID=27356985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/012750 WO1997004748A2 (en) | 1995-08-01 | 1996-08-01 | Enhanced artificial viral envelopes for cellular delivery of therapeutic substances |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6691496A (en) |
WO (1) | WO1997004748A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
US8871444B2 (en) | 2004-10-08 | 2014-10-28 | Medical Research Council | In vitro evolution in microfluidic systems |
US9012390B2 (en) | 2006-08-07 | 2015-04-21 | Raindance Technologies, Inc. | Fluorocarbon emulsion stabilizing surfactants |
US9228229B2 (en) | 2010-02-12 | 2016-01-05 | Raindance Technologies, Inc. | Digital analyte analysis |
US9273308B2 (en) | 2006-05-11 | 2016-03-01 | Raindance Technologies, Inc. | Selection of compartmentalized screening method |
US9328344B2 (en) | 2006-01-11 | 2016-05-03 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
US9448172B2 (en) | 2003-03-31 | 2016-09-20 | Medical Research Council | Selection by compartmentalised screening |
US9498759B2 (en) | 2004-10-12 | 2016-11-22 | President And Fellows Of Harvard College | Compartmentalized screening by microfluidic control |
US9562897B2 (en) | 2010-09-30 | 2017-02-07 | Raindance Technologies, Inc. | Sandwich assays in droplets |
US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
US11965877B2 (en) | 2011-02-18 | 2024-04-23 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997039019A1 (en) * | 1996-04-12 | 1997-10-23 | University Of Pittsburgh | Novel cationic cholesteryl derivatives containing cyclic polar groups |
US6258792B1 (en) | 1996-04-12 | 2001-07-10 | University Of Pittsburgh | Cationic cholesteryl derivatives containing cyclic polar groups |
FR2751222B1 (en) | 1996-07-16 | 1998-10-09 | Capsulis | COMPOSITIONS CONTAINING AT LEAST ONE NUCLEIC ACID AND THEIR APPLICATIONS IN THE BIOMEDICAL FIELD, PARTICULARLY IN GENE THERAPY |
CA2294579C (en) * | 1997-06-23 | 2007-10-09 | Sequus Pharmaceuticals, Inc. | Liposome-entrapped polynucleotide composition and method |
ATE358177T1 (en) | 1997-07-07 | 2007-04-15 | Medical Res Council | AN IN VITRO SORTING PROCESS |
FR2766705B1 (en) * | 1997-07-30 | 2001-05-25 | Biovector Therapeutics | PARTICLE COMPLEX OF NEUTRAL OR NEGATIVE GLOBAL CHARGE FORMED OF A CATIONIC OR NEUTRAL VESICLE AND A BIOLOGICALLY ACTIVE ANIONIC SUBSTANCE, THEIR PREPARATION AND THEIR USE |
FR2766706B1 (en) * | 1997-07-30 | 2001-05-25 | Biovector Therapeutics Sa | STABLE PARTICULATE COMPLEXES OF NEUTRAL OR NEGATIVE GLOBAL LOAD OF MULTILAMELLAR STRUCTURE COMPOSED OF AT LEAST ONE BIOLOGICALLY ACTIVE GLOBALLY ANIONIC SUBSTANCE AND A CATIONIC COMPONENT, THEIR PREPARATION AND USE |
US6372720B1 (en) * | 1998-02-05 | 2002-04-16 | Kenneth J. Longmuir | Liposome fusion and delivery vehicle |
US6903196B1 (en) | 1999-06-17 | 2005-06-07 | Utah Ventures Ii, L.P. | Methods for identifying and isolating tissue-specific lumen-exposed molecules |
GB0015624D0 (en) * | 2000-06-26 | 2000-08-16 | Nat Cancer Centre | Materials and methods relating to improved gene delivery |
WO2002041870A2 (en) * | 2000-11-22 | 2002-05-30 | Vectron Therapeutics Ag | Production and use of a targeted diagnostic system |
AU2002235141A1 (en) | 2000-11-27 | 2002-06-03 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
US7491702B2 (en) | 2001-04-18 | 2009-02-17 | The Open University | Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same |
US7622446B2 (en) | 2001-04-18 | 2009-11-24 | The Open University | Polypeptides, derivatives and uses thereof |
EP1381627B8 (en) * | 2001-04-18 | 2011-01-12 | The Open University | Polypeptides derived from amyloid precursor peptide (app) and their uses |
WO2002088318A2 (en) * | 2001-04-30 | 2002-11-07 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
AU2002312410A1 (en) * | 2001-06-08 | 2002-12-23 | Target Protein Technologies, Inc. | Tissue-specific endothelial membrane proteins |
WO2004039406A1 (en) * | 2002-11-01 | 2004-05-13 | Genomidea Inc. | Medicinal preparation having chemotherapeutic encapsulated therein |
US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
EP2551282A3 (en) | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
WO2008097559A2 (en) | 2007-02-06 | 2008-08-14 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US8592221B2 (en) | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
EP2612868B1 (en) | 2007-11-01 | 2018-08-15 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
WO2010009365A1 (en) | 2008-07-18 | 2010-01-21 | Raindance Technologies, Inc. | Droplet libraries |
EP3415235A1 (en) | 2009-03-23 | 2018-12-19 | Raindance Technologies Inc. | Manipulation of microfluidic droplets |
US10520500B2 (en) | 2009-10-09 | 2019-12-31 | Abdeslam El Harrak | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
WO2011079176A2 (en) | 2009-12-23 | 2011-06-30 | Raindance Technologies, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US9364803B2 (en) | 2011-02-11 | 2016-06-14 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
WO2012167142A2 (en) | 2011-06-02 | 2012-12-06 | Raindance Technolgies, Inc. | Enzyme quantification |
US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
US9340784B2 (en) * | 2012-03-19 | 2016-05-17 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating alpha-1-antitrypsin expression |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
US11193176B2 (en) | 2013-12-31 | 2021-12-07 | Bio-Rad Laboratories, Inc. | Method for detecting and quantifying latent retroviral RNA species |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
SG11202011015QA (en) * | 2018-05-15 | 2020-12-30 | Flagship Pioneering Innovations V Inc | Fusosome compositions and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0475178A1 (en) * | 1990-08-27 | 1992-03-18 | Kabushiki Kaisha Vitamin Kenkyusyo | Liposome for entrapping gene, liposomal preparation and process for the manufacture of the preparation |
EP0497997A1 (en) * | 1991-02-02 | 1992-08-12 | Nika Health Products Limited | Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems |
EP0544292A2 (en) * | 1991-11-27 | 1993-06-02 | Roche Diagnostics GmbH | Method of introduction of nucleic acids in cells |
WO1994018947A1 (en) * | 1993-02-16 | 1994-09-01 | Sharifa Karali | High purity protamine-dna complex and use of same |
WO1996040964A2 (en) * | 1995-06-07 | 1996-12-19 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
-
1996
- 1996-08-01 WO PCT/US1996/012750 patent/WO1997004748A2/en active Application Filing
- 1996-08-01 AU AU66914/96A patent/AU6691496A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0475178A1 (en) * | 1990-08-27 | 1992-03-18 | Kabushiki Kaisha Vitamin Kenkyusyo | Liposome for entrapping gene, liposomal preparation and process for the manufacture of the preparation |
EP0497997A1 (en) * | 1991-02-02 | 1992-08-12 | Nika Health Products Limited | Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems |
EP0544292A2 (en) * | 1991-11-27 | 1993-06-02 | Roche Diagnostics GmbH | Method of introduction of nucleic acids in cells |
WO1994018947A1 (en) * | 1993-02-16 | 1994-09-01 | Sharifa Karali | High purity protamine-dna complex and use of same |
WO1996040964A2 (en) * | 1995-06-07 | 1996-12-19 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9448172B2 (en) | 2003-03-31 | 2016-09-20 | Medical Research Council | Selection by compartmentalised screening |
US8871444B2 (en) | 2004-10-08 | 2014-10-28 | Medical Research Council | In vitro evolution in microfluidic systems |
US9186643B2 (en) | 2004-10-08 | 2015-11-17 | Medical Research Council | In vitro evolution in microfluidic systems |
US9498759B2 (en) | 2004-10-12 | 2016-11-22 | President And Fellows Of Harvard College | Compartmentalized screening by microfluidic control |
US9328344B2 (en) | 2006-01-11 | 2016-05-03 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
US9534216B2 (en) | 2006-01-11 | 2017-01-03 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
US9410151B2 (en) | 2006-01-11 | 2016-08-09 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
US9273308B2 (en) | 2006-05-11 | 2016-03-01 | Raindance Technologies, Inc. | Selection of compartmentalized screening method |
US9012390B2 (en) | 2006-08-07 | 2015-04-21 | Raindance Technologies, Inc. | Fluorocarbon emulsion stabilizing surfactants |
US9498761B2 (en) | 2006-08-07 | 2016-11-22 | Raindance Technologies, Inc. | Fluorocarbon emulsion stabilizing surfactants |
US9228229B2 (en) | 2010-02-12 | 2016-01-05 | Raindance Technologies, Inc. | Digital analyte analysis |
US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
US9562897B2 (en) | 2010-09-30 | 2017-02-07 | Raindance Technologies, Inc. | Sandwich assays in droplets |
US11965877B2 (en) | 2011-02-18 | 2024-04-23 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
Also Published As
Publication number | Publication date |
---|---|
AU6691496A (en) | 1997-02-26 |
WO1997004748A2 (en) | 1997-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997004748A3 (en) | Enhanced artificial viral envelopes for cellular delivery of therapeutic substances | |
WO1997004748B1 (en) | Enhanced artificial viral envelopes for cellular delivery of therapeutic substances | |
CA2154445A1 (en) | Lysosomal targeting of immunogens | |
WO1998004242A3 (en) | Tumor delivery vehicles and method to enhance treatment of cystic tumors | |
UA42089C2 (en) | Influenza vaccine based on envelope antigenic proteins of influenza virus, method for its production | |
WO1999018933A3 (en) | Methods for encapsulating nucleic acids in lipid bilayers | |
AU7599500A (en) | Novel gl50 molecules and uses therefor | |
EP1798239A3 (en) | G-protein coupled receptors and uses therefor | |
WO1997000965A3 (en) | A lipidic vector for nucleic acid delivery | |
CN1140989A (en) | Vesicles with controlled release of actives | |
WO2000034317A3 (en) | Method for reducing immunogenicity of proteins | |
Baru et al. | Liposome-encapsulated DNA-mediated gene transfer and synthesis of human factor IX in mice | |
IL132103A0 (en) | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle | |
CA2159626A1 (en) | Method for delivering beneficial compositions to hair follicles | |
PL362804A1 (en) | Novel b7-4 molecules and uses therefor | |
AU716500B2 (en) | Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs | |
NZ333203A (en) | Tumour antigen proteins, genes thereof, and tumour antigen peptides | |
CA2285667A1 (en) | Viral vectors having chimeric envelope proteins containing the igg-binding domain of protein a | |
WO1995019435A3 (en) | T cell antigen receptor v region proteins and methods of preparation thereof | |
GEP20022734B (en) | Pharmaceutical Preparation Comprising Lyophilized Liposomes Encapsulating an Active Principle Which Is Highly Insoluble in Water, and the Process for Preparing the Said Preparation | |
EP1165125B8 (en) | Antigen-specific induction of peripheral immune tolerance | |
IL128735A0 (en) | Method for tolerizing a mammalian patient to administration of gene therapy virus vectors | |
EP0288520A1 (en) | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof. | |
AU6205998A (en) | Encapsulated cells producing antibodies | |
NO20000990D0 (en) | Methods and compositions of treatments using genes encoding secreted proteins such as interferon <beta> |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US US US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 9,10,59,74 AND 76,DESCRIPTION,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;PAGES 1/18-18/18,DRAWINGS,REPLACED BY NEW PAGES 1/20-20/20;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |